Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review

Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor agreements in countries in Canada, Middle East, Asia, and Australia. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, Italy, Germany, Japan, Australia and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc Key Recent Developments

May 07,2024: Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
Mar 21,2024: Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Feb 21,2024: Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Feb 15,2024: Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Myriad Genetics Inc - Key Facts
Myriad Genetics Inc - Key Employees
Myriad Genetics Inc - Key Employee Biographies
Myriad Genetics Inc - Major Products and Services
Myriad Genetics Inc - History
Myriad Genetics Inc - Company Statement
Myriad Genetics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Myriad Genetics Inc - Business Description
Product Category: Hereditary Cancer
Overview
Performance
Product Category: Pharmacogenomics
Overview
Performance
Product Category: Prenatal
Overview
Performance
Product Category: Tumor Profiling
Overview
Performance
Geographical Segment: Rest of world
Performance
Geographical Segment: United States
Performance
R&D Overview
Myriad Genetics Inc - Corporate Strategy
Myriad Genetics Inc - SWOT Analysis
SWOT Analysis - Overview
Myriad Genetics Inc - Strengths
Myriad Genetics Inc - Weaknesses
Myriad Genetics Inc - Opportunities
Myriad Genetics Inc - Threats
Myriad Genetics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024
Myriad Genetics Inc, Medical Equipment, Deals By Type, 2018 to YTD 2024
Myriad Genetics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 07, 2024: Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
Mar 21, 2024: Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Feb 21, 2024: Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Feb 15, 2024: Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
Jan 30, 2024: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
Jan 09, 2024: Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
Jan 03, 2024: Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Dec 20, 2023: Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
Nov 16, 2023: Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Nov 01, 2023: Myriad Genetics Appoints Sam Raha as Chief Operating Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Myriad Genetics Inc, Key Facts
Myriad Genetics Inc, Key Employees
Myriad Genetics Inc, Key Employee Biographies
Myriad Genetics Inc, Major Products and Services
Myriad Genetics Inc, History
Myriad Genetics Inc, Subsidiaries
Myriad Genetics Inc, Key Competitors
Myriad Genetics Inc, Ratios based on current share price
Myriad Genetics Inc, Annual Ratios
Myriad Genetics Inc, Annual Ratios (Cont...1)
Myriad Genetics Inc, Annual Ratios (Cont...2)
Myriad Genetics Inc, Interim Ratios
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024
Myriad Genetics Inc, Medical Equipment, Deals By Type, 2018 to YTD 2024
Myriad Genetics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Myriad Genetics Inc, Performance Chart (2019 - 2023)
Myriad Genetics Inc, Ratio Charts
Myriad Genetics Inc, Medical Equipment, Deals By Year, 2018 to YTD 2024
Myriad Genetics Inc, Medical Equipment, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings